Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
“Human Medicines” page
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Other National MS Societies (Not listed here)
endMS CONFERENCE
Episode 10 with Dr. Richard Ransohoff on his group's latest research
Episode 31 with Dr. Lloyd Kasper on the gut microbiome and MS
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Episode 16 with Dr. Revere [double-quote]Rip[double-quote] Kinkel on how to improve patient outreach
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Breastfeeding and multiple sclerosis relapses: a meta-analysis.
Episode 13 with Professor Alan Thompson on the International Progressive MS Alliance.
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies.
JOINT CONGRESS OF EUROPEAN NEUROLOGY
Aubagio® significantly reduced risk of new clinical relapse or MRI lesion in multiple sclerosis study
Pharmacokinetics and metabolism of mitoxantrone. A review.
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
Synthetic Biologics announces issuance of U.S. patent covering combination of estriol and Copaxone® for multiple sclerosis
Spotlight on teriflunomide.

Pages